NCT02011139

Brief Summary

Depression is common in end-stage renal disease (ESRD) patients and has a negative effect on the quality of life, functional ability, and mortality, with a prevalence rate as high as 20-25%. However, it is hard to use anti-depressant due to the safety issue, and there has been little data so far particularly in terms of randomized clinical trials. Here, we investigate the effect of cognitive-behavioral group therapy for enhancing mental health and quality of life in patients with ESRD.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
15

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Oct 2013

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2013

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

December 3, 2013

Completed
10 days until next milestone

First Posted

Study publicly available on registry

December 13, 2013

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2014

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2014

Completed
Last Updated

November 20, 2015

Status Verified

November 1, 2015

Enrollment Period

11 months

First QC Date

December 3, 2013

Last Update Submit

November 17, 2015

Conditions

Outcome Measures

Primary Outcomes (1)

  • Beck Depression Inventory-II (BDI-II) score

    3 months

Secondary Outcomes (9)

  • Secondary assessment tools for depression,anxiety, and quality of life

    3 months

  • Secondary assessment tools for depression,anxiety, and quality of life

    3 months

  • Secondary assessment tools for depression,anxiety, and quality of life

    3 months

  • Secondary assessment tools for depression,anxiety, and quality of life

    3 months

  • Secondary assessment tools for depression,anxiety, and quality of life

    3 months

  • +4 more secondary outcomes

Study Arms (2)

Group A

ACTIVE COMPARATOR

12 sessions of Cognitive-behavioral group therapy in the first 12 weeks

Behavioral: Cognitive-behavioral group therapy

Group B

ACTIVE COMPARATOR

12 sessions of Cognitive-behavioral group therapy in the second 12 weeks

Behavioral: Cognitive-behavioral group therapy

Interventions

Group AGroup B

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with end-stage renal disease : on hemodialysis more than 3 months
  • Patients with BDI-II score \>= 15 points
  • Adult with age \>= 20 years old
  • Patients who were able to understand and willing to sign the written informed consent

You may not qualify if:

  • Patients on hemodialysis due to acute kidney injury
  • Patients who are on admission
  • Patients who are undergoing chemotherapy or radiation therapy due to progressive malignant disease
  • Patients who are planning kidney transplantation within few months
  • Patients with cognitive dysfunction, mental retardation, and drug addict
  • Patients who are unavailable for adequate communication with researchers
  • Patients who changed anti-depressive agent or dose within 2 months before/after the trial

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Seoul National University Boramae Hospital

Seoul, South Korea

Location

MeSH Terms

Conditions

Kidney Failure, ChronicDepression

Condition Hierarchy (Ancestors)

Renal Insufficiency, ChronicRenal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsBehavioral SymptomsBehavior

Study Officials

  • Chun Soo Lim, M.D. PhD

    Seoul National University Boramae Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

December 3, 2013

First Posted

December 13, 2013

Study Start

October 1, 2013

Primary Completion

September 1, 2014

Study Completion

December 1, 2014

Last Updated

November 20, 2015

Record last verified: 2015-11

Locations